Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

Mortality from coronavirus disease 2019 (COVID-19) in populations at high risk, such as the elderly, certain ethnic groups (e.g., Black/African American, and Hispanic/Latino persons), obese individuals, and those with endothelial dysfunction is substantial. While treatment options are limited, vaccination against SARS-CoV-2, the virus that causes COVID-19, is the most important global strategy in controlling the pandemic. Thus, two lipid nanoparticle (LNP)-based mRNA vaccines (Pfizer-BioNTech and Moderna) against SARS-CoV-2 have already received emergency use authorization by the US Food and Drug Administration (FDA).